

## First revenues from Salix® Coronary Plaque module

### Fee per scan revenues commence at Tanner Health

**PERTH, Australia, 12 December 2025:** Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce that Tanner Health has commenced commercial use of the Salix® Coronary Plaque module, generating the first fee per scan revenues for Artrya.

### Highlights

- **First fee per scan revenues generated for Salix® Coronary Plaque module with Tanner Health**
- **Tanner Health, a foundational U.S. commercial customer, has successfully expanded their use of the Salix® Coronary Anatomy platform to include assessments with Salix® Coronary Plaque module in their workflow**
- **Expands Artrya U.S. revenue opportunity with subscription revenues and fee per scan assessed with Salix® Coronary Plaque module - supported by U.S. Category 1 CPT reimbursement rate US\$950 for each assessment**

**John Konstantopoulos, Co-Founder and CEO of Artrya commented:**

*"We are thrilled to commence the first clinical use of the Salix® Coronary Plaque module at Tanner Health, which has been well supported by our new U.S. Customer Support team. The ease of activation within the Salix® Coronary Anatomy platform has been well received by the clinicians and the back end processes through to billing are also now established. We look forward to growing adoption across the entire Tanner Health network in the near term, which will generate an attractive ongoing fee to Artrya, from each scan they assess."*

**Shazib Khawaja, MD, FACC, Chair, Heart and Vascular Services, Tanner Health commented:**

*"Tanner Health is excited to be the first health system in the U.S. to use the Salix® Coronary Plaque module and we can see significant benefits to our patients in being able to more rapidly assess and better treat coronary artery disease. The ease of integration and high-quality training from Artrya, all accessed within a single system, is a clear benefit to our already busy workflow."*

### First fee per scan revenues from Salix® Plaque module

Artrya has expanded its collaborative work with Tanner Health, a foundational customer in the U.S., following their five-year commercial agreement with Artrya entered in July 2025. Under that commercial agreement, Tanner Health has completely integrated the Salix® Coronary Anatomy into their workflow and is paying Artrya a monthly subscription fee for the Salix® software. The commercial agreement also included the ability to charge a fee per CCTA scan assessed with the Salix® Coronary Plaque module.

Tanner Health has now activated the use of the FDA cleared Salix® Coronary Plaque module at their primary hospital in Carrollton, Georgia with a roll-out to additional hospitals in the near term. This followed a successful integration led by the new Artrya Customer Support team including training, billing, and reimbursement coding.

Tanner Health can seek U.S. Category 1 CPT reimbursement rate US\$950 for each assessment using the Salix® Coronary Plaque module.

**- Ends -**

This ASX Announcement is authorised for release by the Board of Artrya Limited.

## About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit [www.artrya.com](http://www.artrya.com) or follow us on LinkedIn at [www.linkedin.com/company/artrya](https://www.linkedin.com/company/artrya)

## Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya's business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

## For more information:

### Corporate Enquiries

**John Konstantopoulos**  
Co-Founder and Chief Executive Officer  
Tel: +61 8 6478 7816  
Email: [contact@artrya.com](mailto:contact@artrya.com)

### Investor & Media Enquiries

**David Allen or John Granger**  
Hawkesbury Partners  
Tel: +61 499 100 038 or +61 410 577 155  
Email: [investors@artrya.com](mailto:investors@artrya.com)